To print: Select File and then Print from your browser's menu

Title: Fluticasone Propionate/Salmeterol or Budesonide/Formoterol Inhaler Improves Pulmonary Function, Regardless of Race: Presented at AAAAI

"Fluticasone Propionate/Salmeterol or Budesonide/Formoterol Inhaler Improves Pulmonary Function, Regardless of Race: Presented at AAAAI"

By Maggie Schwarz WASHINGTON, DC -- March 17, 2009 -- Treatment with fixed- and adjustable-dose budesonide/formoterol or fixed-dose fluticasone propionate/salmeterol inhalers improves asthma outcome and is well tolerated regardless of racial group, researchers stated here at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. Shailen R. Shah, MD, Pennsylvania Allergy & Asthma Consultants, Collegeville, Pennsylvania, led a team of investigators in evaluating the efficacy and tolerability of budesonide/formoterol and fluticasone propionate/salmeterol among asthma patients assigned to racial demographic groups of white (n = 670, n = 341, respectively), black (n = 107, n = 50), and other (n = 39, n = 15). The average annual prevalence of asthma in the United States is approximately 9.2% in blacks and 6.9% in whites, with more blacks experiencing asthma exacerbations than whites (5.4% vs 3.9%), according to a National Health Interview Survey 2001-2003, Dr. Shah explained. Whether disparities in disease prevalence and severity in blacks and other racial demographic groups are paralleled by disparities in treatment efficacy is controversial. Speaking here at a poster presentation on March 15, Dr. Shah's group presented the efficacy and tolerability results from a 7-month randomised, prospective, open-label study of budesonide/formoterol pressurised metered-dose inhaler and fluticasone propionate/salmeterol dry-powder inhaler in 1,222 patients with asthma. Forced expiratory volume in 1 second (FEV[₁) was determined from the highest of 3 satisfactory attempts performed at visits 1 through 5. Patients kept daily paper diaries of their peak expiratory flows, asthma symptom scores, nighttime awakenings due to asthma, rescue-medication use, and days free of rescue medication.

Treatment with fixed-dose budesonide/formoterol in patients categorised as white, black, and other, respectively, demonstrated improvement in the following categories: predose FEV₁ (0.15, 0.14, 0.15 L); morning peak expiratory flow (PEF) (31.38, 29.02, 35.63 L/min); nighttime symptoms (scale: 0-3) (-0.36, -0.42, -0.32); and rescue-medication use (-1.29, -1.60, -1.31 inhalations daily).

Treatment with adjustable-dose budesonide/formoterol improved predose FEV₁ (0.13, 0.08, 0.18); morning PEF (35.60, 25.13, 36.95); nighttime symptoms (-0.41, -0.28, -0.43); and rescue-medication use (-1.44, -1.30, -1.46), respectively. Treatment with fixed-dose fluticasone propionate/salmeterol improved predose FEV₁ (0.16, 0.15, 0.08); morning PEF (34.39, 20.30, 47.50); nighttime symptoms (-0.36, -0.40, -0.39); and rescue-medication use (-1.35, -0.95, -1.20), respectively.

The incidence of specific adverse effects varied among racial groups. Headache was the most common adverse event across groups (10.7% to 13.0%). Serious adverse events occurred in 20 (2.0%) white patients, 3 (1.9%) black patients, and 2 (3.7%) other patients.

Both budesonide/formoterol and fluticasone propionate/salmeterol improve asthma outcomes and are well tolerated, regardless of race, Dr. Shah concluded.

Funding for this study was provided by AstraZeneca Pharmaceuticals LP.

[Presentation title: Efficacy and Tolerability of Fixed-Dose (FD) and Adjustable-Dose (AD) Budesonide/Formoterol Pressurized Metered-Dose Inhaler (BUD/FM pMDI) and FD Fluticasone Propionate/Salmeterol Dry Powder Inhaler (FP/SAL DPI) Within Racial Groups. Abstract 295]

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.